Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
Pfizer's ELREXFIO Shows Median Overall Survival Of More Than Two Years In Phase 2 MagnetisMM-3 Study
辉瑞ELREXFIO在2期MagnetisMM-3研究中显示的中位总生存期超过2年。
- Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months
- MagnetisMM-3患者的中位总生存期（OS）为24.6个月，中位无进展生存期（PFS）为17.2个月。
Pfizer Inc. (NYSE:PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
辉瑞公司（NYSE：纽交所）今天宣布了重度预处理复发或难治性多发性骨髓瘤（RRMM）患者elranatamab-bcmm相位2 MagnetisMM-3研究的详细总生存期（OS）结果。该研究表明，枢轴单臂试验的A队列（n = 123）的中位OS为24.6（95％CI，13.4，NE）个月。
资讯热榜
更新时间